Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ANRO vs LYRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANRO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–1 Matrix Metrics)

ANRO Overall Winner 6-Pillar Tally: ANRO 4 – 1 LYRA (1 Tie) Matrix Metrics: ANRO 6 – 1 LYRA

As of Nov 17, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ANRO carries a Unified Composite Score of 34.3/100 (SELL) at $25.12 (N/M Forward P/E, 0.0% operating margin), whereas LYRA carries 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin).

  • Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. ANRO 34.3/100 SELL), ANRO captures the overall institutional head-to-head verdict (6–1 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -25032.0% operating margin) and revenue trajectory (+0.0% vs. -87.2% YoY).
  • Technical & Structure Timing Caution: ANRO is currently in a Breakdown options structure phase (RSI 48.0); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANRO vs LYRA
ANRO NYSE Head-to-Head Winner
Alto Neuroscience Inc.
Pharmaceutical Preparations
$25.12
-7.37% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.03β · 94% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 15.0 Fund 38.0 Flow 64.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.0 · SMA20: $24.87 · SMA50: $25.98
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
TTM Revenue $600,000
Forward P/E N/M
Beta / 30D Vol 0.33β · 248% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -35.3%), weak momentum, RSI 21
RSI-14: 21.5 · SMA20: $1.27 · SMA50: $1.82

6-Pillar Scorecard Institutional Category Breakdown (ANRO 4 – 1 LYRA)

Columns: Metric · ANRO · LYRA
1. Valuation Multiples LYRA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 3.9x
2. Growth & Scale ANRO
Revenue Growth (YoY) +0.0% -87.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $600,000
Market Cap $1.2B $2.3M
3. Profitability & Quality ANRO
Gross Margin N/A N/A
Operating Margin 0.0% -25032.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -46.7% -404.5%
4. Balance Sheet & Cash Flow ANRO
Cash Generation (TTM) -$80M -$32M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $301M Net Cash -404.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANRO
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 79.4% (8th %ile) N/A (N/A)
Put/Call OI Skew 0.04x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANRO (6) vs LYRA (1)
Institutional Metric ANRO LYRA Criterion Row Edge
Market Capitalization
Scale
$1.2B $2.3M Larger Scale ANRO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -87.2% Higher Growth ANRO
Operating Margin (TTM)
Profitability
0.0% -25032.0% Higher Margin ANRO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-46.7% -404.5% Higher ROE ANRO
52-Week Range Position
Momentum
54% ($11–$37) 1% ($0–$38) Stronger Trend ANRO
Beta / 30D Volatility
Risk Regime
2.03β · 94% Vol 0.33β · 248% Vol Lower Realized Risk ANRO
Unified Institutional Score
Composite Signal
34.3 / 100 (SELL) 52.2 / 100 (HOLD) Higher Composite LYRA
Trailing 12M Revenue (USD)
Operating Scale
N/A $600,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$80M ($301M Net Cash) -$32M EBITDA (-404.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANRO +110.25 pp
ANRO: +47.75% · LYRA: -62.5%
3M Horizon ANRO +153.08 pp
ANRO: +65.46% · LYRA: -87.62%
6M Horizon ANRO +187.72 pp
ANRO: +100.58% · LYRA: -87.14%
1Y Horizon ANRO +187.72 pp
ANRO: +100.58% · LYRA: -87.14%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANRO vs LYRA. Trailing 12-month operating profitability (ANRO 0.0% vs LYRA -25032.0%) and valuation multiples (ANRO N/M vs LYRA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ANRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-46.7% · N/M
LYRA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$600,000
Gross MarginN/A
Op. Margin-25032.0%
ROE / Fwd P/E-404.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANRO BREAKDOWN
58d in phase · OBV ACCUMULATION
Current IV 79.4%
IV Percentile 8th %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ANRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LYRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LYRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.3M market capitalization and -25032.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ANRO vs LYRA Key Questions & Quantitative Answers

As of Nov 17, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ANRO carries a Unified Composite Score of 34.3/100 (SELL) at $25.12 (N/M Forward P/E, 0.0% operating margin), whereas LYRA carries 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin). Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. ANRO 34.3/100 SELL), ANRO captures the overall institutional head-to-head verdict (6–1 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -25032.0% operating margin) and revenue trajectory (+0.0% vs. -87.2% YoY). Technical & Structure Timing Caution: ANRO is currently in a Breakdown options structure phase (RSI 48.0); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANRO leads the Growth & Scale pillar: ANRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LYRA at -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin). On trailing 12-month operating scale, ANRO generates N/A in USD-normalized revenue versus $600,000 for LYRA. In operating R&D and SG&A reinvestment, ANRO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LYRA.

LYRA screens cheaper on headline valuation multiples. ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANRO (-46.7% ROE) versus LYRA (-404.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ANRO carries 79.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (2.03β · 94% Vol realized risk). By comparison, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.